Taken together, it would suggest that pharmacological development of PDH agonists to stimulate glucose oxidation (e.g., dichloroacetate) may be a novel therapeutic approach to attenuate diabetic cardiomyopathy, and the generation of Pdha1Cardiac−/− mice will prove to be a valuable tool in confirming the validity of such a strategy. The gene discussed is PDP1; the disease is diabetic cardiomyopathy.